SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid community discussion surrounding a recent shooting and its potential political motivations. The conversation includes speculation about the shooter's background and the broader implications for political rhetoric. Some are also discussing the company's financials and potential stock manipulation.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla ($TSLA) is trending amid discussions of a potential breakout, with bullish traders eyeing targets around $400 and beyond, while some warn of an overextended rally built on hype. Community members are actively debating the strength and sustainability of the stock's upward momentum, as well as its valuation relative to fundamentals. Recent comments from Tesla's chair regarding leadership plans and Elon Musk's focus are also fueling speculation.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates the launch of a Dogecoin ETF, despite some reports of delays. A recent accumulation of DOGE by a publicly traded company has also fueled excitement. Many are speculating on how the ETF will affect price movement, drawing comparisons to Bitcoin and Ethereum's ETF launches.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna's stock is trending downwards amid reports linking COVID-19 vaccines to child deaths and Trump administration scrutiny, sparking concerns about the company's future and government contracts. The community is actively discussing potential manipulation and corruption, while some view the dip as a buying opportunity or anticipate a short squeeze. Despite the negative news, some are optimistic about Moderna's pipeline beyond COVID-19 and its potential in AI-driven cancer treatments.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending due to a mix of factors, including news of collaborations and positive trial results, though some reports about potential COVID vaccine risks are also circulating. Community discussion includes frustration with the stock's performance and speculation about potential catalysts, including buyouts or partnerships. The stock's movements are also being discussed in relation to broader market trends, potential government actions, and competitor activity in the pharmaceutical sector.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recent $20 million investment agreement, sparking discussions about potential market capitalization changes and future news catalysts. The community is actively debating the implications of this investment, alongside speculation about upcoming events and their effect on the stock's price. Some traders are also highlighting the stock's low float and high short interest as potential drivers for significant price movement.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending following regulatory approval from the UK for its acquisition of Oxford Ionics, which the company believes will accelerate its technology roadmap.  While some community members are excited about the deal and the potential for a "squeeze", others express skepticism about the long-term value and profitability of quantum computing companies. Some traders are focused on technical analysis, discussing potential breakouts and short-term trading opportunities.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as discussions swirl around its potential role in a shifting vaccine landscape, particularly with concerns arising about mRNA vaccines and the spotlight on health officials like RFK Jr. The community is focused on Novavax's non-mRNA status and potential benefits from shifts in vaccine recommendations, while also expressing frustration with the company's management and marketing efforts. A key talking point is the potential for new partnerships, especially for the CIC (COVID-Influenza Combination) vaccine, with many speculating on potential deals and their impact.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

ATYR is trending due to anticipation surrounding upcoming data release for their Phase 3 trial, with community members actively discussing potential outcomes and comparing the situation to previous short squeeze events like GME. Bullish sentiment centers around the belief in positive data and a potential short squeeze, while bears, including figures like Martin Shkreli, express skepticism and anticipate a negative outcome. The discussion includes technical analysis, potential price targets, and the overall risk/reward profile of this binary event.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation of a potential takeover bid by Paramount Skydance, sparking significant trading volume and price movement. Community discussions revolve around potential bidding wars, valuation estimates, and the possibility of a deal announcement soon. Some investors are expressing concerns around debt and potential shareholder impact, while others are optimistic about a potential bidding war.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NVCR Overall I&#39;ve been pretty happy with what I&#39;ve been hearing from the investor conferences even if I think ultimately I don&#39;t see the stock moving much until next year. Yes Ashley has less spunk then Doyle but Doyle also enthusiastically and aggressively told investors and analysts they were wrong about the sales implications of Lunar for literally years and that has hurt managements credibility greatly. He could have just said that the company was cautiously optimistic, everyone knows that predicting this stuff is somewhat of a crapshoot but he and management chose not to take this approach and came with consistent roo rah instead. I think this more sober minded transparency I&#39;m seeing from Ashley, coupled with hopefully concrete tangible results next year might restore the stock in the near future.  
 
And while I don&#39;t think there&#39;s any world where Ashley isn&#39;t luxuriating in a villa in the Swiss Alps even with her investment in NVCR tanking, her market buy was a good move.

Gordon Gecko

StockTwits Web

NovoCure Ltd

 Overall I've been pretty happy with what I've been hearing from the investor conferences even if I think ultimately I don't see the stock moving much until next year. Yes Ashley has less spunk then Doyle but Doyle also enthusiastically and aggressively told investors and analysts they were wrong about the sales implications of Lunar for literally years and that has hurt managements credibility greatly. He could have just said that the company was cautiously optimistic, everyone knows that predicting this stuff is somewhat of a crapshoot but he and management chose not to take this approach and came with consistent roo rah instead. I think this more sober minded transparency I'm seeing from Ashley, coupled with hopefully concrete tangible results next year might restore the stock in the near future.  
 
And while I don't think there's any world where Ashley isn't luxuriating in a villa in the Swiss Alps even with her investment in NVCR tanking, her market buy was a good move.

Daniel Smith

Moving away from the optics I also think these conferences pointed to some upside I&#39;m not seeing considered much.  
 
I noticed that Biegelsen, one of the best NVCR analysts didn&#39;t seem to have already been expecting much from a positive Trident readout. But Ashley noted something that I think is easy to miss and might be important in the context of a successful readout. It&#39;s not just that Trident almost by definition should imply more revenue per patient from both the front end(earlier start on TTF) and back-end(longer patient survival) but I think Trident has the potential to accelerate TTF adoption beyond the 30-40% wall they&#39;ve hit in the US.  
 
Currently the way patients are shepherded through the system is typically they see a nuero-surgeon who performs the initial tumor removal, then a radiation oncologist who supervises their radiation treatment, and then lastly a neuro- oncologist who supervises the rest of their care.

Moving away from the optics I also think these conferences pointed to some upside I'm not seeing considered much.  
 
I noticed that Biegelsen, one of the best NVCR analysts didn't seem to have already been expecting much from a positive Trident readout. But Ashley noted something that I think is easy to miss and might be important in the context of a successful readout. It's not just that Trident almost by definition should imply more revenue per patient from both the front end(earlier start on TTF) and back-end(longer patient survival) but I think Trident has the potential to accelerate TTF adoption beyond the 30-40% wall they've hit in the US.  
 
Currently the way patients are shepherded through the system is typically they see a nuero-surgeon who performs the initial tumor removal, then a radiation oncologist who supervises their radiation treatment, and then lastly a neuro- oncologist who supervises the rest of their care.

Given where TTF sits in the current treatment paradigm most prescriptions are likely filled out by neuro-oncologists who are firmly emesshed in the drug culture of cancer treatment and the cultural norms/expectations that come with it. It is this culture that to this day pooh-bahs NVCR&#39;s results because there is no &quot;sham&quot; in their trial design, which is a ridiculous notion but stands nonetheless and is actually strongest in the most influential academic centers.  
 
But the thing is the world of radiation oncology is different. Many of the radiation treatments utilized today have far less robust evidence for effectiveness then TTF does and for many of the same reasons, you&#39;re not going to run a trial with a sham proton beam therapy for example. They don&#39;t do trials in the same way drugs get trialed before introducing radically new treatments. Trident might move TTF into the prescribing hands of the radiation oncologists and I think they will be far easier to sell to.

Given where TTF sits in the current treatment paradigm most prescriptions are likely filled out by neuro-oncologists who are firmly emesshed in the drug culture of cancer treatment and the cultural norms/expectations that come with it. It is this culture that to this day pooh-bahs NVCR's results because there is no "sham" in their trial design, which is a ridiculous notion but stands nonetheless and is actually strongest in the most influential academic centers.  
 
But the thing is the world of radiation oncology is different. Many of the radiation treatments utilized today have far less robust evidence for effectiveness then TTF does and for many of the same reasons, you're not going to run a trial with a sham proton beam therapy for example. They don't do trials in the same way drugs get trialed before introducing radically new treatments. Trident might move TTF into the prescribing hands of the radiation oncologists and I think they will be far easier to sell to.

The same context will hopefully help them with METIS as well.